Download Sample
Loading...
| A01348 | Pages: 215 | Jul 2018 | 17695 Views | | |
| Author(s) : Pallavi Jaiswal & Sayali Shinde | Tables: 116 | Charts: 44 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Anticoagulants Market
Request Now !The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025.
Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. The global anticoagulants industry is anticipated to show significant growth during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders, growing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs in the developing region. Furthermore, increase in number of obese and elderly people, higher unmet needs, and surge in demand of novel therapeutics further support the market growth. However, higher price of NOACs and lack of antidots for NOACs impede the market growth.
Anticoagulants Market Segmentation
The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin and LMWH, vitamin K antagonist, and others. By route of administration, the market is segmented as oral anticoagulant and injectable anticoagulant. The various application markets are atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Get more information on this report : Request Sample Pages
Segment Review
Presently, the NOACs segment is a major revenue-generating segment in the anticoagulants market and is anticipated to show dominance during the forecast period, owing to growing adoption of NOACs in developing countries and rising use of NOACs over the warfarin. Presently, NOACs drugs, such as rivaroxaban, betrixaban, apixaban, edoxaban, and dabigatran, are available in the market. Furthermore, NOACs offer various advantages over the warfarin, such as rapid onset action, lesser interaction with drugs and food, predictable pharmacokinetic action, shorter half-life, and no dietary restriction. These have been further supporting the market growth. On the other side, lack of antidote for NOACs and higher price impede the anticoagulants industry growth.
Get more information on this report : Request Sample Pages
Presently, the atrial fibrillation & heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increased use of anticoagulants in treatment of these conditions. However, DVT is expected to witness fastest market growth, owing to increased prevalence of DVT and technological advancement in diagnosis of DVT.
Get more information on this report : Request Sample Pages
Snapshot of the Asia-Pacific Anticoagulants Market
The Asia-Pacific region represents lucrative opportunities for players operating in the anticoagulants market, attributable to its increasing population base, rising prevalence of cardiovascular disease and VTE, developing economies, improving diagnosis rate, and growing demand for ideal therapeutics. Furthermore, continuous economic development with developing healthcare infrastructure and improving healthcare awareness have been further supporting the market growth. However, treatment expenses for anticoagulant drugs are anticipated to hamper the market growth in Asia-Pacific.
Get more information on this report : Request Sample Pages
The key players profiled in this report of anticoagulants market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc., Portola Pharmaceuticals, Inc., and Sanofi S.A.
Key Benefits
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Increase in prevalence of atrial fibrillation, venous thromboembolism and stroke
3.3.1.2. Rise in number of geriatric population
3.3.1.3. Increase in prevalence of obesity
3.3.1.4. Surge in healthcare expenditures worldwide
3.3.2. Restraints
3.3.2.1. High price of NOACs
3.3.2.2. Poor demand in under developed countries
3.3.3. Opportunity
3.3.3.1. Increase in demand for NOACs
3.3.3.2. Growth opportunities in emerging markets
3.3.4. Impact Analyses
CHAPTER 4: ANTICOAGULANTS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. NOACs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Eliquis market size and forecast
4.2.2.2. Bevyxxa market size and forecast
4.2.2.3. Xarelto market size and forecast
4.2.2.4. Savaysa & Lixiana market size and forecast
4.2.2.5. Pradaxa market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Heparins & LMWH
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Vitamin K Antagonists
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Other Anticoagulant Drugs
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Anticoagulants
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Injectable Anticoagulants
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
CHAPTER 6: ANTICOAGULANTS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Atrial Fibrillation & Heart Attack
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Stroke
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Deep Vein Thrombosis (DVT)
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
6.5. Pulmonary Embolism (PE)
6.5.1. Market size and forecast
6.5.2. Market analysis, by country
6.6. Others
6.6.1. Market size and forecast
6.6.2. Market analysis, by country
CHAPTER 7: ANTICOAGULANTS MARKET BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. anticoagulants market, by drug class
7.2.2.1.2. U.S. anticoagulants market, by route of administration
7.2.2.1.3. U.S. anticoagulants market, by application
7.2.2.2. Canada
7.2.2.2.1. Canada anticoagulants market, by drug class
7.2.2.2.2. Canada anticoagulants market, by route of administration
7.2.2.2.3. Canada anticoagulants market, by application
7.2.2.3. Mexico
7.2.2.3.1. Mexico anticoagulants market, by drug class
7.2.2.3.2. Mexico anticoagulants market, by route of administration
7.2.2.3.3. Mexico anticoagulants market, by application
7.2.3. North America anticoagulants market, by drug class
7.2.4. North America anticoagulants market, by route of administration
7.2.5. North America anticoagulants market, by application
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany anticoagulants market, by drug class
7.3.2.1.2. Germany anticoagulants market, by route of administration
7.3.2.1.3. Germany anticoagulants market, by application
7.3.2.2. France
7.3.2.2.1. France anticoagulants market, by drug class
7.3.2.2.2. France anticoagulants market, by route of administration
7.3.2.2.3. France anticoagulants market, by application
7.3.2.3. UK
7.3.2.3.1. UK anticoagulants market, by drug class
7.3.2.3.2. UK anticoagulants market, by route of administration
7.3.2.3.3. UK anticoagulants market, by application
7.3.2.4. Italy
7.3.2.4.1. Italy anticoagulants market, by drug class
7.3.2.4.2. Italy anticoagulants market, by route of administration
7.3.2.4.3. Italy anticoagulants market, by application
7.3.2.5. Spain
7.3.2.5.1. Spain anticoagulants market, by drug class
7.3.2.5.2. Spain anticoagulants market, by route of administration
7.3.2.5.3. Spain anticoagulants market, by application
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe anticoagulants market, by drug class
7.3.2.6.2. Rest of Europe anticoagulants market, by route of administration
7.3.2.6.3. Rest of Europe anticoagulants market, by application
7.3.3. Europe anticoagulants market, by drug class
7.3.4. Europe anticoagulants market, by route of administration
7.3.5. Europe anticoagulants market, by application
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan anticoagulants market, by drug class
7.4.2.1.2. Japan anticoagulants market, by route of administration
7.4.2.1.3. Japan anticoagulants market, by application
7.4.2.2. China
7.4.2.2.1. China anticoagulants market, by drug class
7.4.2.2.2. China anticoagulants market, by route of administration
7.4.2.2.3. China anticoagulants market, by application
7.4.2.3. Australia
7.4.2.3.1. Australia anticoagulants market, by drug class
7.4.2.3.2. Australia anticoagulants market, by route of administration
7.4.2.3.3. Australia anticoagulants market, by application
7.4.2.4. India
7.4.2.4.1. India anticoagulants market, by drug class
7.4.2.4.2. India anticoagulants market, by route of administration
7.4.2.4.3. India anticoagulants market, by application
7.4.2.5. South Korea
7.4.2.5.1. South Korea anticoagulants market, by drug class
7.4.2.5.2. South Korea anticoagulants market, by route of administration
7.4.2.5.3. South Korea anticoagulants market, by application
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific anticoagulants market, by drug class
7.4.2.6.2. Rest of Asia-Pacific anticoagulants market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific anticoagulants market, by application
7.4.3. Asia-Pacific anticoagulants market, by drug class
7.4.4. Asia-Pacific anticoagulants market, by route of administration
7.4.5. Asia-Pacific anticoagulants market, by application
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil anticoagulants market, by drug class
7.5.2.1.2. Brazil anticoagulants market, by route of administration
7.5.2.1.3. Brazil anticoagulants market, by application
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia anticoagulants market, by drug class
7.5.2.2.2. Saudi Arabia anticoagulants market, by route of administration
7.5.2.2.3. Saudi Arabia anticoagulants market, by application
7.5.2.3. South Africa
7.5.2.3.1. South Africa anticoagulants market, by drug class
7.5.2.3.2. South Africa anticoagulants market, by route of administration
7.5.2.3.3. South Africa anticoagulants market, by application
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA anticoagulants market, by drug class
7.5.2.4.2. Rest of LAMEA anticoagulants market, by route of administration
7.5.2.4.3. Rest of LAMEA anticoagulants market, by application
7.5.3. LAMEA anticoagulants market, by drug class
7.5.4. LAMEA anticoagulants market, by route of administration
7.5.5. LAMEA anticoagulants market, by application
CHAPTER 8: COMPANY PROFILES
8.1. Aspen Holdings
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance
8.2. Bayer AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.3. Boehringer Ingelheim Pharma GmbH & Co. KG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance
8.4. Bristol-Myers Squibb Company
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance
8.5. Daiichi Sankyo Co., Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product Portfolio
8.5.4. Business performance
8.6. GlaxoSmithKline plc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance
8.7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Pfizer Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. Portola Pharmaceuticals, Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Key strategic moves and developments
8.10. Sanofi
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 02. NOAC MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 03. NOAC MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 04. HEPARINS & LMWH MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. VITAMIN K ANTAGONISTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. OTHER ANTICOAGULANT DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 08. ORAL ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. INJECTABLE ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 11. ANTICOAGULANTS MARKET FOR ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2017-2025 ($MILLION)
TABLE 12. ANTICOAGULANTS MARKET FOR STROKE, BY REGION, 2017-2025 ($MILLION)
TABLE 13. ANTICOAGULANTS MARKET FOR DEEP VEIN THROMBOSIS (DVT), BY REGION, 2017-2025 ($MILLION)
TABLE 14. ANTICOAGULANTS MARKET FOR PULMONARY EMBOLISM (PE), BY REGION, 2017-2025 ($MILLION)
TABLE 15. ANTICOAGULANTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 16. ANTICOAGULANTS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 18. U.S. ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 19. U.S. ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 20. U.S. ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 21. CANADA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 22. CANADA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 23. CANADA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 24. MEXICO ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 25. MEXICO ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 26. MEXICO ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 27. NORTH AMERICA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 28. NORTH AMERICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 29. NORTH AMERICA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 30. EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 31. GERMANY ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 32. GERMANY ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 33. GERMANY ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 34. FRANCE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 35. FRANCE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 36. FRANCE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 37. UK ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 38. UK ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 39. UK ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 40. ITALY ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 41. ITALY ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 42. ITALY ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 43. SPAIN ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 44. SPAIN ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. SPAIN ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 46. REST OF EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 47. REST OF EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 48. REST OF EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 49. EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 50. EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 51. EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 52. ASIA- PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 53. JAPAN ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 54. JAPAN ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 55. JAPAN ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 56. CHINA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 57. CHINA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 58. CHINA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 60. AUSTRALIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 61. AUSTRALIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 62. INDIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 63. INDIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 64. INDIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 65. SOUTH KOREA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 66. SOUTH KOREA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 67. SOUTH KOREA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 71. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 72. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 73. ASIA-PACIFIC ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 74. LAMEA ANTICOAGULANTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 75. BRAZIL ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 76. BRAZIL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 77. BRAZIL ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 78. SAUDI ARABIA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 79. SAUDI ARABIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 80. SAUDI ARABIA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 81. SOUTH AFRICA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 82. SOUTH AFRICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 83. SOUTH AFRICA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 84. REST OF LAMEA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 85. REST OF LAMEA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 86. REST OF LAMEA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 87. LAMEA ANTICOAGULANTS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
TABLE 88. LAMEA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 89. LAMEA ANTICOAGULANTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 90. ASPEN: COMPANY SNAPSHOT
TABLE 91. ASPEN: OPERATING SEGMENTS
TABLE 92. ASPEN: PRODUCT PORTFOLIO
TABLE 93. BAYER: COMPANY SNAPSHOT
TABLE 94. BAYER: OPERATING SEGMENTS
TABLE 95. BAYER: PRODUCT PORTFOLIO
TABLE 96. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 97. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 98. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 99. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 100. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 101. DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 102. DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 103. GSK: COMPANY SNAPSHOT
TABLE 104. GSK: OPERATING SEGMENTS
TABLE 105. GSK: PRODUCT PORTFOLIO
TABLE 106. J&J: COMPANY SNAPSHOT
TABLE 107. J&J: OPERATING SEGMENTS
TABLE 108. J&J: PRODUCT PORTFOLIO
TABLE 109. PFIZER: COMPANY SNAPSHOT
TABLE 110. PFIZER: OPERATING SEGMENTS
TABLE 111. PFIZER: PRODUCT PORTFOLIO
TABLE 112. PORTOLA: COMPANY SNAPSHOT
TABLE 113. PORTOLA: PRODUCT PORTFOLIO
TABLE 114. SANOFI: COMPANY SNAPSHOT
TABLE 115. SANOFI: OPERATING SEGMENTS
TABLE 116. SANOFI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ANTICOAGULANTS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL ANTICOAGULANTS MARKET
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05. IMPACT ANALYSES
FIGURE 06. ELIQUIS MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 07. BEVYXXA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 08. XARELTO MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 09. SAVAYSA & & LIXIANA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 10. PRADAXA MARKET REVENUE, 2017-2025 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF NOAC MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF HEPARINS & LMWH MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF VITAMIN K ANTAGONISTS MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTHER ANTICOAGULANT DRUGS MARKET, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF ORAL ANTICOAGULANTS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF INJECTABLE ANTICOAGULANTS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR ATRIAL FIBRILLATION & HEART ATTACK, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR STROKE, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2017 & 2025 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR PULMONARY EMBOLISM (PE), BY COUNTRY, 2017 & 2025 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF ANTICOAGULANTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 22. ASPEN: REVENUES, 2015-2017 ($MILLION)
FIGURE 23. ASPEN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. ASPEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 25. BAYER: REVENUE, 2015-2017 ($MILLION)
FIGURE 26. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. BOEHRINGER INGELHEIM: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. BOEHRINGER INGELHEIM: NET SALES BY BUSINESS, 2017 (%)
FIGURE 29. BOEHRINGER INGELHEIM: NET SALES BY REGION, 2017 (%)
FIGURE 30. REVENUE, 2015-2017 ($MILLION)
FIGURE 31. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 32. DAIICHI SANKYO: NET SALES, 2015-2017 ($MILLION)
FIGURE 33. GSK: REVENUE, 2015-2017 ($MILLION)
FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 36. J&J: REVENUE, 2015-2017 ($MILLION)
FIGURE 37. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Anticoagulants (or blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time. The adoption of anticoagulants is expected to increase during the forecast period, owing to increase in the target patient population across the world and the growth in demand of novel oral anticoagulants (NOACs) among the developing countries.
Increase in prevalence of venous thromboembolism (VTE) and cardiovascular disease and rise in demand of novel therapeutics drive the market growth of the global anticoagulants market. In addition, technological advancement in diagnostic devices and higher number of unmet needs along with growing demand for NOACs in developing countries are projected to supplement the market growth during the forecast period. Furthermore, increasing geriatric population and rising prevalence of obesity have been further supporting the market growth. However, very high price of NOACs and lack of antidote for NOACs hinder the market growth.
North America is expected to remain dominant during the forecast period, owing to increase in the target population, early diagnosis, presence of a large number of trained medical professionals, and higher demand for novel therapeutics. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, owing to its developing healthcare infrastructure with a growing number of target population.
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers